Examining the Latest Advancements in GLP-1-Based Therapies: Combining GLP-1 & Amylin Analogues for Obesity & Diabetes Therapy
Time: 9:00 am - 9:30 am
day: Day One
Details:
- Discussing the complementary physiological actions of GLP-1 and amylin in regulating glucose homeostasis, appetite, and satiety
- Highlighting how the combination of agonists can lead to enhanced glycemic control, weight loss, and improved cardiovascular outcomes compared to monotherapies.
- Explore potential challenges, such as the development of long-acting dual agonists with sustained efficacy and the need for further clinical trials to establish long-term safety and efficacy
